Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 3-18~* Speech disorders verified by speech therapist and neurologist~* Adequate hearing/vision to follow conversation~* Russian speaker~* A written informed consent of the parents/close relatives~Exclusion Criteria:~* Acute infectious disease (bacterial, fungal, or viral)~* Seizures~* Intolerance to gentamicin and/or multiple drug allergies~* Participation in other clinical trials

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal M2-BFs (Type: EXPERIMENTAL): Intranasally-Administered Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs). M2 were generated in vitro from peripheral blood of a parent during 7 days. Cell-free culture medium, containing M2-BFs, was collected, and aliquots of 2 mL/vial were cryopreserved.~30 children with speech disorders will receive their first doses (n=2-3) of M2-BFs in Clinic and wait 2 hrs to determine any short-time adverse effects of inhaled dose. The subsequent course of intranasal inhalations (once a day up to 30 days) performed as outpatient treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).